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During the past decade, a variety of instrument-assisted bacterial identification and antimicrobial
susceptibility test systems have been developed which permit provision of test results in a matter of hours
rather than days, as has been the case with traditional overnight procedures. These newer rapid techniques are
much more expensive than older methods. It has been presumed but not proven that the clinical benefits of
rapid testing to patients with infection offset the added cost. The intent of this study was to objectively define
the clinical impact of rapid bacterial identification and antimicrobial susceptibility testing. A 1-year study was
performed in which infected, hospitalized patients in a tertiary-care, teaching, medical center were randomly
assigned to one of two groups: patients for whom identification and susceptibility testing was performed by
using a semi-automated, rapid, same-day procedure and those for whom testing was accomplished by using
traditional overnight techniques. The two groups were compared with respect to numerous demographic
descriptors, and then patients were monitored prospectively through the end of their hospitalization with the
aim of determining whether there existed objectively defineable differences in management and outcome
between the two groups. The mean lengths of time to provision of susceptibility and identification test results
in the rapid test group were 11.3 and 9.6 h, respectively. In the overnight test group, these values were 19.6 and
25.9 h, respectively (P < 0.0005). There were 273 evaluable patients in the first group and 300 in the second
group. Other than the length of time required to provide susceptibility and identification test results, no
significant differences were noted between the two groups with respect to >100 demographic descriptors. With
regard to measures of outcome, the mean lengths of hospitalization were also the same in both groups.
Mortality rates were, however, lower in the rapid test group (i.e., 8.8% versus 15.3%). Similarly, statistically
significantly fewer laboratory studies, imaging procedures, days of intubation, and days in an intensive or
intermediate-care area were observed with patients in the rapid test group. Rapid testing was also associated
with significantly shortened lengths of elapsed time prior to alterations in antimicrobial therapy. Lastly,
patient costs for hospitalization were significantly lower in the rapid test group. The results of this study
indicate the rapid same-day bacterial identification and susceptibility testing in the microbiology laboratory
can have a major impact on the care and outcome of hospitalized patients with infection.
The identification of clinically significant bacteria in the
laboratory and the performance of in vitro susceptibility tests
provide information essential to the effective management of
patients with infectious diseases (7). During the past two
decades, a variety of instrument-assisted identification and
susceptibility test methods have been developed which permit
generation of test results in a period of 2 to 7 h, as opposed to
the 15- to 24-h time frame previously required with traditional
overnight methods. These newer techniques are often referred
to as "rapid" methods and, in general, have been shown to
provide test results nearly as accurate as those derived from
traditional overnight tests. Rapid methods are, however, more
expensive. Their added cost notwithstanding, these newer
rapid methods have been widely adopted in United States
clinical microbiology laboratories.
In view of the added cost of rapid identification and suscep-
tibility test methods, the question arises, what is their clinical
impact? Stated another way, can the added cost of these
methods be justified on the basis of some definable contribu-
tion of the method to clinical care? It has been hypothesized
that rapid susceptibility testing might lead to shortened re-
* Corresponding author. Mailing address: Clinical Microbiology
Laboratories, University of Massachusetts Medical Center, 55 Lake
Ave. North, Worcester, MA 01655. Phone: (508) 856-6417. Fax: (508)
856-1206.
sponse times in cases where antibiotic therapy needs to be
altered (2). Indeed, the results of two published studies
indicate that rapid susceptibility tests significantly influenced
clinician usage of antibiotics (3, 6). Other reports provide
conflicting results (4). We are aware of no published investi-
gations that have actually attempted to systematically assess
the impact of rapid susceptibility testing on infectious disease
outcome. Similarly, we know of no published studies that have
examined the clinical impact of rapid bacterial identification.
These were the objectives of the controlled, prospective,
randomized study reported herein.
MATERIALS AND METHODS
Study design. During a 1-year period, all specimens received
in the University of Massachusetts Medical Center Clinical
Microbiology Laboratories from hospitalized patients were
assigned to one of two categories based on the first letter of the
last name of the patient from whom the specimen had been
obtained (A through K and L through Z). Previous experience
indicated that roughly half of the laboratory's specimens came
from patients in each group. Specimens were processed by
standard methods. When bacteria were recovered and deter-
mined by standard laboratory criteria to merit identification
and performance of in vitro susceptibility tests, such tests
were performed by using a rapid 2- to 7-h instrument-assisted
1757
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TABLE 1. Comparison of patient groups with respect
to several characteristics
Number (%) of patients in:
Category and
subcategorya RAST ONAST p5
group group
Service
Medicine 111 (40.7) 133 (44.3) NS
Surgery 105 (38.5) 107 (35.7) NS
Pediatrics 30 (11.0) 32 (10.7) NS
Others 27 (9.0) 28 (9.3) NS
Diseasec
Nonfatal 115 (42.1) 147 (49.0) NS
Possible fatal 99 (36.3) 100 (33.3) NS
Rapidly fatal 21 (7.7) 32 (10.7) NS
Ultimately fatal 34 (12.4) 21 (7.0) 0.027
Infection
Community acquired 164 (60.1) 190 (63.3) NS
Nosocomial 109 (39.9) 110 (36.7) NS
Antibiotic allergy
All antibiotics 43 (15.8) 33 (11.0) NS
Penicillins 27 (9.9) 26 (8.7) NS
Immunocompromised
HIVC positive 5 (1.8) 5 (1.7) NS
Autoimmune disorder 0 1 (0.3) NS
Malignancy 29 (10.6) 31 (11.4) NS
Steroid therapy 32 (11.7) 26 (8.7) NS
Total 34 (12.5) 38 (12.6) NS
Index positive culture
Urine 100 (36.6) 125 (41.7) NS
Blood 42 (15.4) 45 (15.0) NS
Wound 60 (22.0) 63 (21.0) NS
LRT 43 (15.8) 40 (13.3) NS
Body fluid 26 (9.5) 26 (8.7) NS
Other 2 (0.7) 1 (0.3) NS
aHIV, human immunodeficiency virus; LRT, lower respiratory tract.b NS, not significant; i.e., P > 0.05.
cDisease categories are defined in the text.
test method, the Baxter-Microscan WALKAWAY-96 System
(Baxter-Microscan, Sacramento, Calif.) (W/A), with commer-
cially available reagents. The Microscan Rapids test panels
employ fluorogenic enzyme substrates and fluorimetry as
means for rapidly determining bacterial identification and
susceptibility test results. Susceptibility tests were performed in
a breakpoint broth microdilution format with results expressed
in the form of susceptibility categories (resistant, intermediate,
moderately susceptible, or susceptible). With patients in the
A-K group, identification and susceptibility tests were initiated
immediately upon recognition of bacterial growth, usually
sometime between 8:00 and 11:00 a.m. As a result, test results
were usually available on the same day. This group was
referred to as the rapid antimicrobial susceptibility test
(RAST) group. With patients in the L-Z group, identification
and susceptibility tests were initiated between 9:00 and 10:00
p.m. on the evening of the day of recognition of growth such
that test results were effectively not available until the follow-
ing morning at ca. 8:30 a.m. The laboratory was not staffed
during the third shift. This second group was referred to as the
overnight antimicrobial susceptibility test (ONAST) group.
Reporting of results. The results of identification and sus-
ceptibility tests in both the RAST and ONAST groups were
telephoned as soon as they became available by members of
the laboratory's technologist staff directly to the physician who
had requested the analysis with all isolates recovered from
blood cultures, normally sterile body fluids, catheter tips
yielding .15 colonies, specimens obtained in the operating
TABLE 2. Comparison of groups based on primary
infectious disease problems
Number (%) of
Infectious disease patients in:
or condition' RAST ONAST
group group
Uncomplicated UTI 70 87 NS
Complicated UTI 30 38 NS
Line-related bacteremia 21 15 <0.005
Urosepsis 5 9 NS
Endocarditis 1 0 NS
Bacteremia from other source 15 21 NS
Catheter site infection 2 1 NS
Cellulitis 10 10 NS
Postsurgical 22 21 NS
Chronic ulcer 12 13 NS
Other wounds 9 11 NS
Bone or joint infection 7 8 NS
Tracheobronchitis 12 7 NS
Pneumonia 31 33 NS
Pneumonia with empyema 2 0 NS
Intra-abdominal infection 20 25 NS
Meningitis 4 1 NS
a UTI, urinary tract infection.
b See Table 1, footnoteb.
room, and selected other important specimens. All other test
results were reported by using a computerized laboratory
information system that had been in place for approximately 8
years. As soon as identification and susceptibility test results
became available from the W/A instrument, they were trans-
ferred to the laboratory computer thereby becoming accessible
to the clinical staff through use of an inquiry routine. In
addition, hard copies of all test results were distributed to
patients' medical records sometime between 2:00 and 5:00 a.m.
the day after they first became available.
Inclusion criteria. Only patients from whom a clinically
significant isolate of Staphylococcus aureus, non-aureus staph-
ylococci, Acinetobacter spp., or a member of the Enterobacte-
riaceae had been recovered from a representative specimen
were included in the study. The study was restricted to patients
with infections due to these organisms since we believed that at
the time this study was performed, only these organisms would
yield reliable susceptibility test results with the W/A system
when used in the rapid mode. The first specimen from which
one or more of these organisms was recovered was defined as
the index positive specimen. Immediately following enrollment
in the study, patients were assigned to either a third-year
clinical pathology resident (R.V.) or a third-year infectious
disease fellow (M.G.) for evaluation and data gathering. All
study patients were followed prospectively throughout their
hospitalization in the context of numerous demographic de-
scriptors (see Tables 1 to 4), with respect to antibiotic usage,
numerous parameters of disease outcome, and cost of hospi-
talization (see Tables 5 to 7 and text). Information was
tabulated by using the Fourth Dimension data base program
on a Macintosh Ilci computer.
Statistical analyses. Paired t tests, chi square analysis, and
Fisher's exact test were used for statistical analyses.
RESULTS
There were 273 evaluable patients (52.0% males) in the
RAST group and 300 evaluable patients (46.0% males) in the
ONAST group. The mean age of patients in the RAST group
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TABLE 3. Comparison of patient groups with respect to bacteria recovered from index positive culture
No. of organisms recovered in RAST/ONAST groups'
Organism
Blood Body fluid LRT Urine Wound Other Total
Staphylococcus aureus 12/13 4/3 30/17 3/3 36/40 1/0 86/76
Non-aureus staphylococcus 11/12 7/4 5/3 13/10 1/1 37/30
Eschenichia coli 13/10 13/18 1/7 66/87 4/6 97/128
Enterobacter spp. 1/2 1/1 2/11 6/7 2/7 12/28
Klebsiella spp. 5/5 6/2 5/5 17/26 0/6 33/44
Other enterics 4/4 2/3 8/6 16/20 6/5 36/38
Acinetobacter spp. 2/2 1/0 3/5 1/1 1/6 8/14
Total 48/48 34/31 49/51 114/147 62/80 2/1 309/358
a Among the totals (both organism and specimen), results were statistically significantly different in only two cases, i.e. total numbers of isolates of Staphylococcus
aureus (P = 0.047) and Enterobacter spp. (P = 0.032). LRT, lower respiratory tract.
was 51.3 years (range = 1 to 94; standard deviation [SD] =
25.0). In the ONAST group, the mean age was 53.7 years
(range = 1 to 96; SD = 26.2). These differences were not
statistically significant. When patient ages were analyzed by
increments of 10 years as opposed to mean age, again no
differences were seen. The two groups of patients were ana-
lyzed with respect to clinical service, severity of underlying
disease, origin of the index positive infection (community
acquired or nosocomial), presence or absence of antibiotic
allergy, existence of immunocompromising condition (and if
so, which one), and specimen source for their index positive
culture (Table 1). Regarding severity of underlying disease, a
modification of the criteria of McCabe (5) were employed in
which four categories were defined: 1, nonfatal (conditions not
expected to alter life span, with a -<5% chance of hospital
mortality [e.g., pneumonia in a healthy young adult, cellulitis,
and urosepsis without shock, etc.]); 2, possibly fatal (conditions
which were potentially treatable or curable [i.e., not rapidly or
ultimately fatal] but which had the potential for altering life
span and/or a 5 to 10% chance of hospital mortality [e.g.,
pneumonia in the elderly and complicated valve replacement,
etc.]); 3, ultimately fatal (conditions with >80% chance of
mortality within 1 to 3 years regardless of intervention [e.g.,
cirrhosis with liver failure, metastatic cancer, and AIDS, etc.]);
and 4, rapidly fatal (conditions with >80% chance of death
within 6 to 12 months regardless of intervention [e.g., end stage
cancer or end-stage AIDS, etc.]). Significant differences be-
tween the two groups were noted for only one parameter:
12.4% of patients in the RAST group were judged to have an
ultimately fatal underlying disease versus 7.0% of patients in
the ONAST group. When antibiotic allergies were examined
according to individual agents, no differences between the
RAST and ONAST groups were noted (data not shown).
Patient groups were also analyzed from the perspective of
the specialty or subspecialty service primarily responsible for
an individual patient's management at the time of the index
positive culture (data not shown). Again, no significant differ-
ences were found.
The primary infections patients were noted to have at the
time of the index positive culture are depicted in Table 2. With
one exception, no significant differences were noted between
the RAST and ONAST groups. Significantly more patients
(i.e., 21) in the first group had line-related bacteremia than in
the second group (i.e., 15).
Table 3 lists those bacteria that were isolated from index
positive cultures in the two patient groups. Only minor differ-
ences between the two groups were apparent. The number of
isolates of staphylococci, Acinetobacter spp., and enteric gram-
negative bacilli recovered from index positive cultures ex-
ceeded the number of actual specimens in most specimen
categories. This reflects the fact that selected specimens
yielded more than one organism. Table 3 lists only those
bacteria recovered from index positive cultures upon which the
rapid identification and susceptibility tests were performed.
Selected other bacteria were also recovered from index posi-
tive specimens. These included aerobic diphtheroids, Moraxella
catarrhalis, viridans streptococci, beta-hemolytic streptococci,
Streptococcus pneumoniae, Enterococcus spp., Haemophilus
spp., Neisseria spp., various anaerobes, Pseudomonas aerugi-
nosa, and other miscellaneous gram-negative bacilli. The fre-
quencies with which one or more of these bacteria were
isolated from index positive specimens obtained from patients
in the RAST group and the ONAST group, respectively, were
as follows: blood cultures, 5 and 2; body fluids, 32 and 57; lower
respiratory tract secretions, 29 and 18; urine specimens, 16 and
13; and wound specimens, 42 and 48.
In the RAST patient group, 230 of 273 patients (84.2%)
were receiving antibiotic therapy at the time of the index
positive culture; 277 of the 300 patients in the ONAST group
(92.3%) were receiving antibiotics. These percentages were
not statistically significantly different. Table 4 provides a
comparison of patients in the two groups who were receiving
antibiotics at the time of the index positive culture. No
significant differences between the two groups were observed
with respect to the reasons for therapy, routes of administra-
TABLE 4. Comparison of groups with respect to antibiotic therapy
at the time of the index positive culture
Administration of Activity against No. of patients
antibiotic(s) presumed with therapy in
directed against Route of prpathogen(s) groupyinfection assessed administration ptogen
byindexpositive ~from indexby index positive positive culture RAST ONASTculture
Yes IV/IM Yes 164 198
No 11 10
PO Yes 38 52
No 3 2
No IV/IM Yes 7 11
No 8 8
PO Yes 2 3
No 2 2
b IV, intravenous; IM, intramuscular, PO, oral.
d p values were not significant for any results.
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TABLE 5. Comparison of patient groups based on length of hospitalization and mortality rates
Result for group
Characteristic P
RAST ONAST
Mean total length (days) of hospitalization (range [SD]) 20.7 (2-129 [20.7]) 20.1 (2-133 [20.0]) NS
Mean length of hospitalization (days) following index positive culture 14.7 (0-118 [17.6]) 14.6 (1-118 [16.5]) NS
(range [SD])
Total no. (%) of patient deaths 24 (8.8) 46 (15.3) 0.016
Total no. (%) of patient deaths attributable to infection 19 (7.0) 38 (12.7) 0.023
tion, and activity of the agents patients were receiving against Having determined that the two patient groups were essen-
their presumed infecting pathogens. Similarly, the RAST and tially comparable except for the much shorter period of time to
ONAST patients were comparable in terms of those specific provision of organism identification and susceptibility test
antibiotics patients were receiving at the time of the index results in the RAST group, it was of interest to compare and
positive culture and the percentage of patients who were contrast the two groups in the context of various indicators of
receiving combination versus single-agent therapy (data not disease outcome, with respect to cost of hospitalization, and in
shown). terms of impact on antibiotic therapy.
The mean length of time to positivity of index positive The two patient groups were comparable when analyzed
cultures in the RAST group, i.e., 24.8 h (range = 10.2 to 123; according to length of hospitalization, both total and that
SD = 14.0) was nearly identical to that observed in the following the index positive culture (Table 5). Mortality rates,
ONAST group, i.e., 23.9 h (range = 10.2 to 123; SD = 10.3). however, both overall and those attributable to infection, were
Statistically significant differences between the RAST and significantly lower in the RAST group than in the ONAST
ONAST groups were, however, noted with respect to the mean group. The frequency with which microbiology tests were
length of time to a definitive identification of the presumed performed on study patients was assessed, as were the numbers
infecting pathogen(s) in the index positive culture and the of blood cultures obtained and the numbers of significant
average time period required before susceptibility test results positive blood cultures (Table 6). Data were analyzed with
were available. In the RAST group, these values were 11.3 h respect to entire hospitalizations and for that specific period of
(range = 0.5 to 77; SD = 14.4) and 9.6 h (range = 4 to 68; SD hospitalization that followed the index positive culture. During
= 13.2), respectively. In contrast, in the ONAST group, these both periods, statistically significantly fewer microbiology tests,
values were 19.9 h (range = 0.5 to 101; SD = 15.5) and 25.9 h blood cultures, and positive blood cultures were noted in the
(range = 16 to 78; SD = 11.0), respectively. These differences RAST group than in the ONAST group. The frequencies with
were highly statistically significant (P < 0.0005). which eight other laboratory tests were performed for the two
TABLE 6. Frequency with which various procedures were performed on patients in the two groups
RAST group ONAST group
Procedure" Total no. Mean no. of tests/ No. (%) of Total no. Mean no. of tests/ No. (%) of p
of tests patient (range [SD]) patients of tests patient (range [SD]) patientsofetsien range[SD]) getting test getting test
Microbiology tests
During hospitalization 4,597 16.8 (0-98 [8.4]) 273 (100) 5,833 19.4 (0-117 [9.0]) 300 (100) 0.0006
Post-index positive culture 3,778 13.8 (0-74 [8.1]) 273 (100) 4,830 16.1 (0-90 [11.2]) 300 (100) 0.0054
Blood cultures
During hospitalization 1,665 6.1 (0-28 [4.6]) 212 (77.7) 2,649 8.8 (0-40 [4.0]) 260 (86.7) <0.0005
Post-index positive culture 1,338 4.9 (0-21 [3.2]) 201 (73.6) 2,250 7.5 (0-29 [4.0]) 238 (79.3) <0.0005
Significant positive blood cultures
During hospitalization 190 0.7 (0-8 [0.6]) 56 (20.5) 343 1.1 (0-11 [1.0]) 60 (20.0) <0.0005
Post-index positive culture 148 0.5 (0-5 [0.9]) 26 (9.5) 298 1.0 (0-7 [0.9]) 31 (10.3) <0.0005
Urinalysis 957 3.5 (0-38 [2.0]) 248 (90.8) 1,176 3.9 (0-34 [2.1]) 299 (99.7) 0.0199
Blood glucose 1,880 6.9 (0-98 [4.3]) 245 (89.7) 2,660 8.9 (0-104 [4.8]) 285 (95.0) <0.0005
Electrolytes 2,503 9.2 (0-126 [7.1]) 248 (90.8) 3,402 11.3 (0-140 [8.0]) 292 (97.3) 0.0100
Chemical profile 1,229 4.5 (0-80 [4.2]) 219 (80.2) 1,633 5.4 (0-66 [4.3]) 270 (90.0) 0.0116
Complete blood count 5,675 20.8 (0-378 [18.3]) 255 (93.4) 7,930 26.4 (0-578 [24.7]) 300 (100) 0.0023
Differential 2,639 9.7 (0-178 [8.8]) 245 (89.7) 3,448 11.5 (0-162 [8.9]) 300 (100) 0.0153
Arterial blood gas 5,501 20.2 (0-660 [22.8]) 164 (60.1) 8,630 28.8 (0-738 [40.6]) 169 (56.3) 0.0021
Serum antibiotic assay 761 2.8 (0-32 [2.9]) 140 (51.3) 1,515 5.1 (0-94 [4.5]) 118 (39.3) <0.0005
Electrocardiogram 1,355 5.0 (0-88 [4.9]) 172 (63.0) 1,421 4.8 (0-52 [4.8]) 223 (74.3) NS
CT scan 325 1.2 (0-12 [1.0]) 161 (59.0) 398 1.3 (0-18 [1.1]) 125 (41.7) NS
Chest X-ray 3,206 11.7 (0-37 [8.3]) 180 (66.0) 4,243 14.1 (0-42 [7.9]) 199 (66.3) <0.0005
Abdominal X-ray 386 1.4 (0-8 [0.9]) 82 (30.0) 531 1.8 (0-7 [0.8]) 106 (35.3) 0.0006
Ultrasound 76 0.3 (0-4 [0.2]) 56 (20.5) 107 0.4 (0-10 [0.3]) 61 (20.3) <0.0005
Days of intubation 1,482 5.4 (0-78 [6.4]) 76 (27.8) 2,457 8.2 (0-93 [7.0]) 96 (32.0) 0.0014
Days in an ICA 646 2.4 (0-41 [3.6]) 48 (17.6) 1,010 3.4 (0-50 [4.2]) 61 (20.3) 0.0024
Days in an ICU 1,320 4.8 (0-69 [5.0]) 68 (24.9) 1,904 6.3 (0-81 [8.0]) 80 (26.7) 0.0135
a ICA, intermediate-care area; ICU, intensive care unit.
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TABLE 7. Comparison of costs incurred by patients in the two groups
Cost (dollars) incurred per patient in:
Category RAST group ONAST group
P value
Mean Range SD Mean Range SD
Laboratory costs 4,732 178-98,314 5,650 6,074 24-169,700 7,111 0.0132
Microbiology costs 843 22-14,949 1,202 1,240 33-17,222 1,515 0.0006
Pharmacy costs 4,181 24-56,539 4,070 5,523 43-111,927 4,930 <0.0005
Antibiotic costs 1,063 28-8,260 809 1,354 33-31,179 1,077 0.0044
Other costsa 6,149 521-129,182 8,222 7,659 64-109,098 8,042 0.0269
Total 15,062 1,165-260,187 17,661 19,256 1,780-298,975 21,644 0.0118
a Room charges, radiology and nuclear medicine procedures, ventilatory assistance, and respiratory, physical, and nutritional therapy, etc.
groups were compared (Table 6). Again in all eight cases, the
test frequency in the RAST group was significantly lower than
in the ONAST group. Five different noninvasive diagnostic
procedures were tracked (Table 6). The frequencies with which
electrocardiograms and computerized tomography (CT) scans
were performed were similar in the two groups; however,
ultrasound, chest X-ray, and abdominal X-ray were performed
significantly less frequently in the RAST group. Finally, days of
intubation and days in an intensive or intermediate-care area
were compared between the two groups (Table 6). In all three
cases, values in the RAST group were statistically significantly
lower than in the ONAST group.
Patients in the two groups were compared with respect to
the impact of rapid testing on antibiotic therapy. Among the
230 patients in the RAST group who were receiving an
antibiotic(s) at the time of the index positive culture, 105
(45.6%) had therapy altered within 24 h of receipt of suscep-
tibility test results; in the ONAST group these figures were 110
of 277 patients (39.7%) (P = 0.2046). All 43 patients in the
RAST group and all 23 patients in the ONAST group who had
not been receiving antibiotics at the time of the index positive
cultures had therapy initiated within 24 h of receipt of suscep-
tibility test results. The percentages of patients in both groups
who had antibiotics switched, added, or dropped were equiva-
lent (data not shown). So were the percentages of patients
changed to oral therapy (data not shown). The frequencies
with which changes in therapy appeared to have been predi-
cated on in vitro test results, concerns for toxicity, and/or
awareness of cost were not statistically significantly different in
the two patient groups (data not shown). The only statistically
significant difference related to antibiotic therapy was the
mean length of time following recognition of growth in index
positive cultures that passed prior to implementation of
changes in therapy, i.e., 16.3 h in the RAST group versus 31.2
h in the ONAST group (P = < 0.0005).
The results of an analysis of patient costs incurred during
hospitalization in the two patient groups are depicted in Table
7. Costs were lumped into one of three categories; laboratory,
pharmacy, and all others. In addition, laboratory costs specif-
ically related to microbiology and pharmacy costs specifically
related to antibiotics were determined. In all five cases, costs
incurred by patients in the RAST group were statistically
significantly lower than those in the ONAST group. The total
mean cost of hospitalization in the RAST group ($15,063) was
significantly lower than the total mean cost of hospitalization in
the ONAST group ($19,257).
DISCUSSION
The intent of the current study was to assess the clinical
impact of rapid bacterial identification and in vitro suscepti-
bility testing in the setting of an academic medical center
referral hospital. We are unaware of previous published stud-
ies that have examined this issue. The study was prospective in
design and benefitted from a control group of patients who
were found to be nearly identical to patients in the study group
with respect to numerous demographic characteristics. The
single salient difference between the two groups was that
patients in the study group had bacterial isolates processed by
using a susceptibility and identification test system which
generated information on the same day tests were initiated. In
the control group, the results of susceptibility test and identi-
fication procedures were available on the day following per-
formance of the test.
A routine result reporting scheme was employed whose
general features, at least, are comparable to systems used in
most tertiary-care hospitals. No effort was made to expedite
result reporting. Clearly, the mechanism used to report labo-
ratory results can have a major impact on how information is
used (1, 4, 6). By using a routine, fairly typical, and widely
applied result reporting scheme, we attempted to eliminate the
influence of reporting as a variable on outcome. Furthermore,
it was hoped that the results of this study would be generally
applicable to other institutions of similar composition and
scope of activities.
The two patient populations did not differ with respect to
length of hospitalization. Mortality rates, however, both in
general and mortality directly attributable to infection, were
lower in the rapid test group than in the overnight test group.
Length of hospitalization and mortality are extremely crude
measures of outcome. In an attempt to examine clinical impact
in a more refined manner, the frequencies of various proce-
dures that might be related to disease outcome were compared
between the two groups. Among a total of 19 different
parameters, in only two cases, i.e., the frequency with which
electrocardiograms and CT scans were performed, were the
two patient groups found to be the same. In all other cases,
significantly fewer procedures were performed among patients
in the rapid test group versus those in the overnight test group.
These included microbiology tests, subsequent significant pos-
itive blood cultures, various other laboratory studies, serum
antibiotic assays, several imaging procedures, days of intuba-
tion, and length of time spent in either an intensive or
intermediate-care area.
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We also examined the impact of rapid microbiology testing
on antibiotic usage. Interestingly, rapid tests were not found to
influence physician selection of therapeutic agents in the
context of any of the parameters we tracked. The only differ-
ence noted was that in patients in whom a change in therapy
was made following performance of laboratory tests, i.e., ca.
half of all patients in both groups, the change in therapy was
instituted, on the average, ca. 15 h sooner in the rapid test
group than in the overnight test group. The mean length of
time to a change in therapy was 16.3 h in the former group and
31.2 h in the latter. This difference was highly statistically
significant and was roughly comparable to the mean differ-
ences between the length of time required to generate test
results in the rapid group versus the overnight group for both
susceptibility tests and bacterial identification. In other words,
the principal benefit of rapid tests on antibiotic therapy was
provision of test information sooner so that changes in therapy,
when indicated, could be implemented more quickly.
Perhaps not surprising in view of the foregoing, the costs of
hospitalization for patients in the two groups varied signifi-
cantly. Laboratory costs, pharmacy costs, and other general
costs were significantly lower in the rapid test group than in the
overnight test group. If we amortized the cost savings to
patients over a 1-year period in our institution, the total savings
would have been $2,403,162.
Of interest in this study was the observation that despite an
apparent impact of rapid microbiology tests on numerous param-
eters directly and indirectly related to disease outcome, we
observed no effect on length of hospitalization. One possible
explanation for this observation is that the parameters we as-
sessed were largely related to the outcome of infectious diseases,
and that in a tertiary-care teaching medical center where patient
acuity is typically high, factors other than infectious disease
problems have the greatest influence on length of hospitalization,
the most obvious being the underlying diseases that caused
patients to be hospitalized in the first place.
In conclusion, the results of the current study suggest that
same-day in vitro susceptibility testing and bacterial identification
can have a demonstrable clinical impact and are associated with
significant cost savings for patients. In addition, rapid testing may
be related to lower mortality rates in patients with infection.
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